EBNA-1 anticorps (AA 551-641) (Cy5)

N° du produit ABIN1415465

Détail du produit anti-EBNA-1 anticorps (Cy5)

Antigène: EBNA-1 (Epstein-Barr Virus Nuclear Antigen-1 (EBNA-1))

Épitope: AA 551-641

Reactivité: Epstein-Barr Virus (EBV), Virus

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp EBNA-1 est conjugé à/à la Cy5

Application: Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Réactivité croisée: Virus

Réactivité croisée (Details): Epstein Barr Virus

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from EBV Nuclear Antigen

Isotype: IgG

Information d'application

Indications d'application: IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Date de péremption: 12 months

Détails sur EBNA-1

Antigène: EBNA-1 (Epstein-Barr Virus Nuclear Antigen-1 (EBNA-1))

Autre désignation: EBV Nuclear Antigen (EBNA-1 Produits)

Synonymes: anticorps EBNA-1, anticorps latency protein, anticorps CeHV15gEBNA-1, anticorps EBNA-1, anticorps HHV4tp2_gp36

Classe de substances: Viral Protein

Sujet:

Synonyms: EBNA1, EBNA-1, EBV nuclear antigen 1, Epstein Barr nuclear antigen 1, Epstein Barr virus, BKRF1, Epstein-Barr nuclear antigen 1, EBV nuclear antigen 1,

Background: Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) is the one EBV antigen that is expressed in all EBV associated malignancies. It has long been thought to go undetected by the cell mediated immune system. However, recent studies show that EBNA1 can be presented to both CD4+ and CD8+ T cells, making it a potential new target for immunotherapy of EBV related cancers.